United Therapeutics (UTHR) Short Interest Ratio & Short Volume $297.33 -0.83 (-0.28%) Closing price 04:00 PM EasternExtended Trading$297.51 +0.18 (+0.06%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock United Therapeutics Short Interest DataUnited Therapeutics (UTHR) has a short interest of 75,600 shares, representing 0.19% of the float (the number of shares available for trading by the public). This marks a -95.30% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.3, indicating that it would take 0.3 days of the average trading volume of 442,900 shares to cover all short positions.Current Short Interest75,600 sharesPrevious Short Interest1,610,000 sharesChange Vs. Previous Month-95.30%Dollar Volume Sold Short$21.72 millionShort Interest Ratio0.3 Days to CoverLast Record DateJune 30, 2025Outstanding Shares45,110,000 sharesShort Percent of Float0.19%Today's Trading Volume459,518 sharesAverage Trading Volume442,900 sharesToday's Volume Vs. Average104% Short Selling United Therapeutics? Sign up to receive the latest short interest report for United Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartUTHR Short Interest Over TimeUTHR Days to Cover Over TimeUTHR Percentage of Float Shorted Over Time United Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/202575,600 shares $21.72 million -95.3%0.2%0.3 $287.35 6/15/20251,610,000 shares $456.19 million -14.4%3.7%2.9 $283.35 5/31/20251,880,000 shares $594.72 million -10.5%4.3%3.7 $316.34 5/15/20252,100,000 shares $638.23 million +6.6%4.8%4.1 $303.92 4/30/20251,970,000 shares $597.09 million +18.7%4.5%3.9 $303.09 4/15/20251,660,000 shares $472.80 million -2.9%3.8%3.4 $284.82 3/31/20251,710,000 shares $527.14 million -6.6%3.9%3.6 $308.27 3/15/20251,830,000 shares $562.25 million -25.6%4.2%4.1 $307.24 2/28/20252,460,000 shares $787.10 million +18.8%5.6%6.1 $319.96 2/15/20252,070,000 shares $767.10 million +3.0%4.7%5.8 $370.58 Get the Latest News and Ratings for UTHR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20252,010,000 shares $705.85 million +1.5%4.6%6.3 $351.17 1/15/20251,980,000 shares $716.05 million +3.1%4.5%6.2 $361.64 12/31/20241,920,000 shares $677.45 million -14.3%4.4%6.1 $352.84 12/15/20242,240,000 shares $810.45 million +7.7%5.1%6.8 $361.81 11/30/20242,080,000 shares $770.62 million -5.9%4.8%6.1 $370.49 11/15/20242,210,000 shares $802.78 million -3.9%5.0%6.1 $363.25 10/31/20242,300,000 shares $860.13 million +5.0%5.2%5.8 $373.97 10/15/20242,190,000 shares $787.46 million -2.2%5.0%5.3 $359.57 9/30/20242,240,000 shares $802.70 million -45.1%5.1%5.1 $358.35 9/15/20244,080,000 shares $1.38 billion -0.2%9.3%8.4 $339.12 8/31/20244,090,000 shares $1.49 billion -1.2%9.4%7.8 $363.55 8/15/20244,140,000 shares $1.34 billion +0.5%9.5%7.5 $323.08 7/31/20244,120,000 shares $1.29 billion -1.2%9.4%7.7 $313.29 7/15/20244,170,000 shares $1.36 billion -5.4%9.6%7.4 $327.26 6/30/20244,410,000 shares $1.40 billion +0.9%10.1%7.8 $318.55 6/15/20244,370,000 shares $1.26 billion +12.3%10.0%7.5 $288.06 5/31/20243,890,000 shares $1.07 billion +3.2%9.4%7.2 $275.13 5/15/20243,770,000 shares $1.03 billion -2.1%9.1%7.2 $272.69 4/30/20243,850,000 shares $902.17 million -10.9%9.4%7.4 $234.33 4/15/20244,320,000 shares $1.02 billion -11.7%10.0%9.4 $235.08 3/31/20244,890,000 shares $1.12 billion +154.7%11.3%11.3 $229.72 3/15/20241,920,000 shares $452.70 million +64.1%4.4%4.7 $235.78 2/29/20241,170,000 shares $264.00 million +0.9%2.7%3 $225.64 2/15/20241,160,000 shares $248.87 million +11.5%2.7%3.3 $214.54 1/31/20241,040,000 shares $223.37 million -11.9%N/A3.3 $214.78 1/15/20241,180,000 shares $258.48 million +7.3%N/A3.6 $219.05 12/31/20231,100,000 shares $241.88 million -15.4%N/A3.5 $219.89 12/15/20231,300,000 shares $320.39 million +14.0%N/A4.2 $246.45 11/30/20231,140,000 shares $273.60 million +0.9%N/A4.2 $240.00 11/15/20231,130,000 shares $259.06 million +4.6%N/A4.4 $229.26A new rule goes live in July — and the banks are quietly cashing in (Ad)A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.To help you get started, we're giving away a FREE Wealth Protection Guide that shows you exactly how 10/31/20231,080,000 shares $240.69 million +4.9%N/A3.6 $222.86 10/15/20231,030,000 shares $240.15 million +7.1%N/A3.4 $233.16 9/30/2023962,200 shares $217.33 million -13.3%N/A3.1 $225.87 9/15/20231,110,000 shares $244.47 million +1.8%N/A3.4 $220.24 8/31/20231,090,000 shares $244.55 million -42.3%N/A3.3 $224.36 8/15/20231,890,000 shares $445.53 million +94.6%N/A5.1 $235.73 7/31/2023971,100 shares $235.71 million -2.2%N/A2.7 $242.72 7/15/2023992,600 shares $230.28 million -8.1%N/A2.6 $232.00 6/30/20231,080,000 shares $238.41 million -5.3%N/A2.8 $220.75 6/15/20231,140,000 shares $261.73 million +9.6%N/A2.7 $229.59 5/31/20231,040,000 shares $218.13 million -22.4%N/A2.2 $209.74 5/15/20231,340,000 shares $287.30 million -8.2%N/A2.4 $214.40 4/30/20231,460,000 shares $335.99 million +6.6%N/A2.5 $230.13 4/15/20231,370,000 shares $313.35 million -3.5%N/A2.5 $228.72 3/31/20231,420,000 shares $318.02 million +6.0%N/A2.6 $223.96 3/15/20231,340,000 shares $291.45 million +0.8%N/A2.6 $217.50 2/28/20231,330,000 shares $327.23 million -5.0%N/A2.8 $246.04 2/15/20231,400,000 shares $354.70 million +11.1%3.1%3.6 $253.36 1/31/20231,260,000 shares $331.59 million -3.8%2.8%3.5 $263.17 1/15/20231,310,000 shares $341.96 million -1.5%2.9%3.4 $261.04 12/30/20221,330,000 shares $369.86 million +20.9%3.0%3.5 $278.09 12/15/20221,100,000 shares $303.44 million -17.9%2.5%3 $275.85 11/30/20221,340,000 shares $375.05 million -5.0%3.0%3.6 $279.89 11/15/20221,410,000 shares $365.36 million +6.8%3.2%3.8 $259.12 10/31/20221,320,000 shares $304.30 million -7.0%3.0%3.5 $230.53 10/15/20221,420,000 shares $307.34 million +6.8%3.2%3.9 $216.44 9/30/20221,330,000 shares $278.48 million +7.3%3.0%3.5 $209.38 9/15/20221,240,000 shares $273.59 million +41.4%2.8%3.1 $220.64 8/31/2022877,000 shares $198.75 million -18.0%2.0%2 $226.62 8/15/20221,070,000 shares $233.65 million +1.9%2.4%2.2 $218.36 7/31/20221,050,000 shares $242.62 million -11.0%2.4%2.1 $231.07 7/15/20221,180,000 shares $283.29 million -3.3%2.7%2.4 $240.08 6/30/20221,220,000 shares $287.48 million -6.9%2.8%2.5 $235.64 6/15/20221,310,000 shares $288.32 million -16.0%3.0%2.6 $220.09 5/31/20221,560,000 shares $359.33 million -12.4%3.5%3.2 $230.34 5/15/20221,780,000 shares $326.52 million +58.9%4.0%3.6 $183.44 4/30/20221,120,000 shares $198.87 million +8.7%2.5%2.5 $177.56 4/15/20221,030,000 shares $197.67 million -38.3%2.3%2.3 $191.91 3/31/20221,670,000 shares $299.61 million +67.0%3.8%3.5 $179.41 3/15/20221,000,000 shares $178.82 million -32.0%2.3%2.3 $178.82 2/28/20221,470,000 shares $244.31 million -8.1%3.3%3.4 $166.20 2/15/20221,600,000 shares $326.86 million -9.6%3.6%3.8 $204.29 1/31/20221,770,000 shares $357.31 million +37.2%4.0%4.5 $201.87 1/15/20221,290,000 shares $276.01 million +19.4%2.9%3.1 $213.96 12/31/20211,080,000 shares $233.37 million -21.7%2.5%2.7 $216.08 12/15/20211,380,000 shares $269.96 million -22.0%3.1%3.4 $195.62 11/30/20211,770,000 shares $335.42 million -5.9%4.0%4.6 $189.50 11/15/20211,880,000 shares $385.46 million -21.3%4.3%5.1 $205.03 10/29/20212,390,000 shares $455.92 million +18.3%5.4%6.5 $190.76 10/15/20212,020,000 shares $377.88 million -14.4%4.5%5.5 $187.07A new rule goes live in July — and the banks are quietly cashing in (Ad)A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.To help you get started, we're giving away a FREE Wealth Protection Guide that shows you exactly how 9/30/20212,360,000 shares $435.61 million -4.5%5.3%7 $184.58 9/15/20212,470,000 shares $504.55 million -23.8%5.6%7.6 $204.27 8/31/20213,240,000 shares $696.21 million +68.8%7.4%9.8 $214.88 8/13/20211,920,000 shares $389.03 million +18.5%4.4%5.4 $202.62 7/30/20211,620,000 shares $294.73 million -3.6%3.7%4.7 $181.93 7/15/20211,680,000 shares $309.44 million -4.6%3.8%5.5 $184.19 6/30/20211,760,000 shares $315.76 million No Change4.0%5.4 $179.41 6/15/20211,760,000 shares $314.07 million +0.6%4.0%4.6 $178.45 5/28/20211,750,000 shares $325.33 million -3.9%4.0%4.5 $185.90 5/14/20211,820,000 shares $352.66 million -9.9%4.2%4.8 $193.77 4/30/20212,020,000 shares $412.56 million No Change4.6%5.4 $204.24 4/15/20212,020,000 shares $409.62 million -13.7%4.7%5.5 $202.78 3/31/20212,340,000 shares $387.20 million +3.1%5.4%6 $165.47 3/15/20212,270,000 shares $362.07 million +18.2%5.2%6.7 $159.50 2/26/20211,920,000 shares $324.10 million +10.3%4.4%5.7 $168.80 2/12/20211,740,000 shares $294.98 million -1.1%4.0%5.4 $169.53 1/29/20211,760,000 shares $289.33 million +1.2%4.1%5.2 $164.39 1/15/20211,740,000 shares $291.03 million -7.9%4.0%4.4 $167.26 12/31/20201,890,000 shares $281.01 million -5.0%4.4%4.5 $148.68 12/15/20201,990,000 shares $284.85 million -3.9%4.6%4.9 $143.14 11/30/20202,070,000 shares $280.57 million -7.2%4.8%5.2 $135.54 10/30/20202,520,000 shares $328.23 million +12.5%5.8%6.8 $130.25 10/15/20202,240,000 shares $246.31 million +9.8%5.2%6.9 $109.96 9/30/20202,040,000 shares $206.04 million +10.9%4.7%7 $101.00 9/15/20201,840,000 shares $194.58 million No Change4.3%5.4 $105.75 8/31/20201,840,000 shares $196.81 million +10.8%4.3%4.7 $106.96 8/14/20201,660,000 shares $181.72 million -0.6%3.8%3.7 $109.47 7/31/20201,670,000 shares $186.15 million -13.5%3.9%3.2 $111.47 UTHR Short Interest - Frequently Asked Questions What is United Therapeutics' current short interest? Short interest is the volume of United Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 30th, traders have sold 75,600 shares of UTHR short. 0.19% of United Therapeutics' shares are currently sold short. Learn More on United Therapeutics' current short interest. Which institutional investors are shorting United Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of United Therapeutics: Jane Street Group LLC, Parallax Volatility Advisers L.P., Caption Management LLC, Nomura Holdings Inc., Walleye Trading LLC, Simplex Trading LLC, and Genus Capital Management Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for United Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.19% of United Therapeutics' floating shares are currently sold short. Is United Therapeutics' short interest increasing or decreasing? United Therapeutics saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 75,600 shares, a drop of 95.3% from the previous total of 1,610,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does United Therapeutics' short interest compare to its competitors? 0.19% of United Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to United Therapeutics: Alnylam Pharmaceuticals, Inc. (2.59%), Biogen Inc. (2.74%), Incyte Corporation (3.82%), Neurocrine Biosciences, Inc. (3.75%), Exelixis, Inc. (7.34%), BioMarin Pharmaceutical Inc. (3.43%), Exact Sciences Corporation (3.77%), Halozyme Therapeutics, Inc. (8.35%), Madrigal Pharmaceuticals, Inc. (22.78%), Repligen Corporation (7.10%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short United Therapeutics stock? Short selling UTHR is an investing strategy that aims to generate trading profit from United Therapeutics as its price is falling. UTHR shares are trading down $0.83 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against United Therapeutics? A short squeeze for United Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of UTHR, which in turn drives the price of the stock up even further. How often is United Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including UTHR, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies ALNY Short Squeeze BIIB Short Squeeze INCY Short Squeeze NBIX Short Squeeze EXEL Short Squeeze BMRN Short Squeeze EXAS Short Squeeze HALO Short Squeeze MDGL Short Squeeze RGEN Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:UTHR) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UTHR Stock Alerts